TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06376734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Accelerated TMS will be provided for 2 days using the same dosing regimen as the FDA-cleared SAINT protocol, ten 9-minute treatments per day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Accelerated TMS will be provided for 2 days using the same dosing regimen as the FDA-cleared SAINT protocol, ten 9-minute treatments per day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Accelerated TMS will be provided for 2 days using the same dosing regimen as the FDA-cleared SAINT protocol, ten 9-minute treatments per day.
Study: NCT05226598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations
Study: NCT06228248

Intervention type: OTHER
Intervention: metagenomics
Description: Feces used for metagenomic testing

Intervention type: OTHER
Intervention: metagenomics
Description: Feces used for metagenomic testing
Study: NCT05226598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin 10 mg/ml administered as IV infusion Q3W for 4 administrations
Study: NCT04832152

Intervention type: OTHER
Group type: OTHER
Intervention: OT4ASD
Description: Occupational therapy will focus on education and coaching of families/caregivers of children with autism spectrum disorder to help them adapt their daily routines to address their child's sensory needs.
Study: NCT05888233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Single arm of Allopurinol treatment for 300mg/daily for 4 weeks then increased to 600mg/daily for an additional 4 weeks.
Study: NCT05626335

Intervention type: DIAGNOSTIC_TEST
Intervention: Intraoral scan
Description: On the day of debonding, directly following retainer bonding, intraoral scans were performed (T0), using 3Shape Trios 4 (3Shape, Copenhagen, Denmark). The scans were repeated after a month. The patients were invited for repeating the scans after 1 (T1), 3 (T2) and 6 months (T3).
Study: NCT05830539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018+PLD
Description: IN10018 orally once daily; PLD 40mg/m2, Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018+PLD
Description: IN10018 orally once daily; PLD 40mg/m2, Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018+PLD
Description: IN10018 orally once daily; PLD 40mg/m2, Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018+PLD+Toripalimab
Description: IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018+PLD+Toripalimab
Description: IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018+PLD+Toripalimab
Description: IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018+PLD+Toripalimab
Description: IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018+PLD+Toripalimab
Description: IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018+PLD+Toripalimab
Description: IN10018 orally once daily; PLD 40mg/m2, Q4W; Toripalimab 3 mg/kg, Q2W
Study: NCT05531942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo Diterpene Lactone Meglumine Injection
Description: The injection was diluted with 250ml physiological saline,intravenous drip for about 3 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid (Aspirin) given at a dose of 100 mg/d for 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Acetylsalicylic acid (Aspirin) given at a dose of 100 mg/d for 90 days.
Study: NCT05143411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRE-test
Description: we are going to verify glucose levels before (pre) and after (post) the use of the mobile application.
Study: NCT05226195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile Kinesio Taping
Description: The standard post-surgical protocol and sterile EDF kinesio-taping will be applied to this group in the operating room at the end of the surgery in a sterile manner according to the epidermis-dermis-fascia (EDF) technique previously described in the literature (without tension). Original KinesioTex® Tape will be used in the study. The day of taping will be considered as Day 0 and the tapes will be changed on the 4th day, the 7th day.
Study: NCT05226598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations
Study: NCT05061836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer acetate
Description: Patient will receive Acetate Ringer's solution (Acetar) infused at maintenance rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.25%Dextrose equivalence
Description: 5%dextrose in normal saline (5%DNSS) infused ¼ of maintenance rate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5%Dextrose equivalence
Description: 5%dextrose in normal saline (5%DNSS) infused ½ of maintenance rate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5
Description: 5%dextrose in normal saline (5%DNSS) infused with maintenance rate
Study: NCT05199844

Intervention type: DEVICE
Intervention: Apple Watch
Description: Apple Watch device measures heart rate and oxygen saturation
Study: NCT06466642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ©
Description: The intervention combines Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) and BrainHQ. This integrated program helps individuals with cognitive impairment improve daily activities and achieve work, social, and daily living goals. CogSMART uses compensatory techniques to enhance prospective memory (remembering to do things), attention, learning/memory, and executive functioning (problem-solving, planning, organization, and cognitive flexibility). BrainHQ complements CogSMART with stimulating, game-like modules focusing on memory, attention, and executive functions. Together, they provide a comprehensive therapeutic tool to support cognitive impairment treatments and can also be used as a brain-training tool to prevent memory loss and maintain cognitive abilities.
Study: NCT04227379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention 1- DD-TXT
Description: Participants in this group were signed up for an interactive, tailored self-management texting protocol (DD-TXT). The DD-TXT protocol consisted of the same daily educational content as the DSE arm augmented by the following: regular two-way check-in messages about diabetes self-management behaviors, an invitation to receive messages written by other Veterans living with diabetes on demand, and a menu of optional and customizable modules (e.g., medication reminders, blood sugar and blood pressure monitoring,: physical activity reminders, weight management, and goal setting) from which participants could select messaging that supported their diabetes self-management goals. Patients could customize the timing and frequency of their messages. DD-TXT participants also received a once monthly message asking whether the messages had been helpful.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison - DSE
Description: Participants in the comparison condition were signed up for a one-way education-only protocol called Diabetes Skilled Education-Only (DSE). DSE was comprised of 6 months of once daily one-way text messages covering standard diabetes self-management education content. Starting with the VA educational workbook entitled Self-Care Skills for the Person with Diabetes, created in alignment with VA/DoD diabetes guidelines, we enhanced the educational content by incorporating Veteran input through a co-design process with Veterans living with diabetes and expert clinician review. DSE messages could not be customized. There was no interactive content for the DSE arm other than a once monthly message asking whether the messages had been helpful.
Study: NCT05226598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations
Study: NCT06150742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Niyad (nafamostat mesylate)
Description: Niyad (nafamostat mesylate) lyophilized

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% NaCl)
Description: 0.9% NaCl
Study: NCT05492045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553
Description: D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553
Description: D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other
Description: Standard treatment of NSCLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other
Description: Standard treatment of NSCLC.
Study: NCT05377723

Intervention type: DEVICE
Group type: OTHER
Intervention: Neodyne Device
Description: See Arm Description: Neodyne Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neodyne Device
Description: See Arm Description: Neodyne Device
Study: NCT05226598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations
Study: NCT05120609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parkinson's Application
Description: The application delivers at-home, tailored allied health exercises (physiotherapy, speech and language therapy, and occupational therapy) for the gait, speech, and manual dexterity symptoms associated with Parkinson's disease.
Study: NCT06663475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TTM-based health education videos about smoking cessation for expectant fathers
Description: Tailored for expectant fathers, this smoking cessation health education information will be developed based on transtheoretical model to motivate a quit attempt and maintain abstinence by using videos.
Study: NCT06712043

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Historical control group
Description: Aerobic training (see study Voet 2024, Both aerobic exercise and cognitive-behavioral therapy reduce chronic fatigue in FSHD)
Study: NCT06712771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSA003
Description: subcutaneous injections
Study: NCT06663475

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care treatment
Description: general health education videos about hazards of smoking for expectant fathers in obstetric clinic
Study: NCT06660121

Intervention type: PROCEDURE
Intervention: Electrochemotherapy with bleomycin
Description: Electrochemotherapy (ECT) with bleomycin is a localized treatment approach used for managing desmoid fibromatosis, a benign but locally aggressive tumor. This technique combines electrical pulses with the administration of bleomycin, a chemotherapeutic agent, to enhance drug uptake into tumor cells. The electrical pulses create temporary pores in the cell membranes, allowing bleomycin to enter more effectively, leading to increased cytotoxicity. ECT is typically performed on patients who have not responded to conventional therapies or for whom surgery is not feasible. ECT can lead to significant tumor shrinkage and improvement in symptoms, making it a promising option in the multidisciplinary management of desmoid fibromatosis.
Study: NCT06594588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Moderate-intensity aerobic exercise for 30-50 minutes three times a week was added to usual medical therapy
Study: NCT06616649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulator implant
Description: Participants will receive intervention in the operating room setting
Study: NCT06593067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambient Heating
Description: Description: Ambient heat stress (no higher than 47°C) with and without evaporative (water sprayed on the skin) and convective (electric fan) cooling i.e., no cooling, convective cooling, evaporative cooling, and convection + evaporative cooling.
Study: NCT05087342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 2.4mg
Description: The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be given to the control group per the schedule outlined in the armed description.
Study: NCT04498767

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Each lesion may be treated with 1, 3, or 5 SBRT fractions of 16-24 Gy, 24-33 Gy or 25-40 Gy, respectively, depending on the local practice and size \& location of oligometastases. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments must be completed within 2 weeks (10 working days) in order to avoid delays in starting systemic therapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Palliative RT
Description: Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Patients in this arm should not receive stereotactic doses or radiotherapy boosts, unless there is a clearly known clinical benefit (e.g. stereotactic radiation to a new brain metastases when all disease is controlled on systemic therapy).
Study: NCT06638723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance and fall recovery training
Description: Following the video observation described in the arms, participants will undergo training to physically practice the motor tasks. The training will take place over a 2-week period encompassing 40 practice trials for each task over the training sessions. During training, the investigators will continuously monitor the changes in balance and fall recovery task performance, and will provide feedback. Participants can request to re-watch the demonstration video that they were assigned to at any time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance and fall recovery training
Description: Following the video observation described in the arms, participants will undergo training to physically practice the motor tasks. The training will take place over a 2-week period encompassing 40 practice trials for each task over the training sessions. During training, the investigators will continuously monitor the changes in balance and fall recovery task performance, and will provide feedback. Participants can request to re-watch the demonstration video that they were assigned to at any time.
Study: NCT06636760

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains the non-active carrier of herbal combination that has no pharmacological activity.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: herbal compound
Description: The herbal combination is made up of various medicinal plants and possesses immunomodulator properties. It comprises Phyllanthus niruri, Andrographis paniculata, and Glycyrrhiza glabra, along with Anacardium occidentale leaf and Zingiber officinale rhizome, all recognized for their immunomodulatory properties.
Study: NCT06640556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: watching animation show
Description: The intervention group will watch the animation titled 'A Green Future with the Hand of a Midwife' on days 7, 21, and 30 to mothers who have just given birth, and the scale will be evaluated on three separate days in total.
Study: NCT06616077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized Progesterone 600 mg
Description: Vaginal supplementary micronized progesterone will be given after postovulatory administration of the progesterone receptor antagonist mifepristone. Administration from LH+3 to LH+5 (LH peak=LH+0); 200 mg 3 times per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized Progesterone 600 mg
Description: Vaginal supplementary micronized progesterone will be given after postovulatory administration of the progesterone receptor antagonist mifepristone. Administration from LH+3 to LH+5 (LH peak=LH+0); 200 mg 3 times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone 200 mg
Description: Post ovulatory single oral administration (LH+2, LH peak=LH+0)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mifepristone 200 mg
Description: Post ovulatory single oral administration (LH+2, LH peak=LH+0)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Placebo Tablet
Description: Oral placebo tablet containing brewer yeast, cellulose, stearic acid, silica, magnesium stearate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo Tablet
Description: Oral placebo tablet containing brewer yeast, cellulose, stearic acid, silica, magnesium stearate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal
Description: Cocoa butter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal
Description: Cocoa butter
Study: NCT06678321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobil game
Description: Participants in the intervention group will be asked to play the game and complete all parts.
Study: NCT06679634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoplaque also referred to as Episcleral Topotecan
Description: Sustained Release Episcleral Topotecan
Study: NCT06677983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioflex Crowns
Description: A preformed crown of similar size will be selected. Tooth preparation will be done using a tapered diamond bur to reduce the occlusal surface, including the central groove, by 1-1.5 mm. The proximal surfaces will be prepared by approximately 0.5 mm to clear the contact area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stainless steel crown
Description: An appropriately sized preformed stainless-steel crown will be selected. Tooth preparation will involve using a tapered bur ) to reduce the occlusal surface by 1 to 1.5 mm, with interproximal reduction made on the mesial and distal sides. The selected crown size will be checked, and a trial fit will be conducted prior to cementation. Crimping pliers will be used, and the crown will be cemented with Type 1 glass ionomer cement. Any excess cement will be removed, and proper occlusion will be verified.
Study: NCT06642805

Intervention type: PROCEDURE
Intervention: duodenal atresia
Description: surgery for duodenal atresia
Study: NCT05120609

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Digital Placebo Application
Description: The application is designed to provide a method of capturing outcome measures without providing access to the therapy exercises.
Study: NCT06712771

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injections
Study: NCT06708429

Intervention type: DIAGNOSTIC_TEST
Intervention: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
Description: A combination of blood-based, mucosal-based, and hair-based analyses that evaluate the presence and the expression of:~* a set of microRNAs (blood)~* antibodies anti-frame shift peptides (blood)~* mucosal-resident bacteria (healthy mucosa and cancer)~* environmental exposure to potential carcinogens (hair matrix)

Intervention type: DIAGNOSTIC_TEST
Intervention: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
Description: A combination of blood-based, mucosal-based, and hair-based analyses that evaluate the presence and the expression of:~* a set of microRNAs (blood)~* antibodies anti-frame shift peptides (blood)~* mucosal-resident bacteria (healthy mucosa and cancer)~* environmental exposure to potential carcinogens (hair matrix)

Intervention type: DIAGNOSTIC_TEST
Intervention: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
Description: A combination of blood-based, mucosal-based, and hair-based analyses that evaluate the presence and the expression of:~* a set of microRNAs (blood)~* antibodies anti-frame shift peptides (blood)~* mucosal-resident bacteria (healthy mucosa and cancer)~* environmental exposure to potential carcinogens (hair matrix)
Study: NCT06561087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by injections
Study: NCT06561126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory, Learning and Action Based Intervention
Description: The total number of participants exposed to the intervention (adapted from the DMagic trial in Bangladesh) will be determined based on random selection from the community. A PLA-based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.
Study: NCT05812170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational online session about PF
Description: The educational online session will last 90 minutes, as follows: 10 minutes of contextualization, 40 minutes of practical content about pelvic floor consciousness and 40 of theoretical content (anatomy and practices related to PFD).
Study: NCT05752032

Intervention type: GENETIC
Intervention: ICM-203
Description: Long term follow-up

Intervention type: DRUG
Intervention: Placebo
Description: Long term follow-up
Study: NCT06679569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium 0.2 mg/kg/hr continuous infusion
Description: To maintain Train-of-four count 1 to 3 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.2 mg/kg/hr to achieve and sustain moderate neuromuscular blockade.